RE:RE:News: Lymphing along to better days...LinksBearDownAZ, I believe this study was intended to illustrate peripheral (outside the CNS) distribution of xB3-001 in non-human primates (NHPs). The NHPs did not have brain tumours. Target engagement in the brain can't happen unless there's a target in there. My guess is that Bioasis saw what it's seen in the past with other forms of MTf(p)-TZM, that xB3-001 crosses the BBB but with no target (no job to do), xB3-001 would likely break down quickly and be pushed back across the BBB.
At some point we may learn more of the details of the distribution of xB3-001 throughout the periphery, but for now all that Bioasis seems willing to say is that the distribution was more selective than Herceptin alone. I would guess that this selective distribution has something to do with the distribution of LRP-1 receptors in the periphery. We've had indications in the past that Herceptin delivered by Transcend / xB3 appears to be slightly more efficacious in the periphery than Herceptin alone. Maybe the details of this selective distribution will explain the improvement.
I don't see the accumulation of xB3-001 in lymph nodes as a surrogate for BBB penetration. Today's announcement is about new discoveries about and behaviour of xB3-001. The penetration of the lymph system by xB3-001 is a great discovery. This attribute may represent new opportunities for Bioasis while the selective distribution adds to our undestanding of how xB3-001 behaves the way it does in the periphery.
Good stuff, all the way around.
jdstox